ClinicalTrials.Veeva

Menu

Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms

A

Air Force Military Medical University of People's Liberation Army

Status

Unknown

Conditions

Major Depressive Disorder
Rheumatoid Arthritis

Treatments

Device: Transcutaneous electrical vagus nerve stimulation
Device: Sham vagus nerve stimulation
Drug: drug treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT04037111
82554333

Details and patient eligibility

About

This study is expected to include 90 patients with major depressive disorder and rheumatoid arthritis as study subjects.Randomly divided into 3 groups: drug + VNS stimulation group, drug + sham stimulation group and drug group, each group had 30 patients.The treatment period of each group was 8 weeks.Age and sex were matched in all three groups.Scale evaluation and inflammatory factor test were performed before treatment (baseline), at week 4 and week 8 after treatment.Head MRI, evoked potential, and electrocardiogram were performed at baseline and at the end of week 8.

Full description

  1. Drug +VNS stimulation group: both VNS and escitalopram oxalate tablets were treated for 2 months. VNS stimulation was treated once a day for 30 minutes at the intensity of 1-2mA. Drug treatment: the dose of escitalopram oxalate tablets was maintained at 10-20 mg/ day
  2. Drug + sham stimulation group: the patients were treated with escitalopram oxalate tablets and sham VNS for 2 months. Sham VNS stimulation: the sham stimulation device automatically stops after 30 seconds of stimulation. Drug treatment was the same as the above group.
  3. Drug group: the dose of escitalopram oxalate tablets was maintained at 10-20 mg/ day without VNS stimulation

Enrollment

90 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18-65 years old, in accordance with DSM-5 diagnostic criteria for major depressive disorder, or meet the diagnostic criteria for rheumatoid arthritis. The major depressive disorder is first or at least not used in the 5 half-life of the drug. Antidepressants, antipsychotics or anticonvulsants.
  • Hamilton Depression Rating Scale (HAMD) 17 scores over 17 points.

Exclusion criteria

  • Brain organic lesions (such as cerebral hemorrhage, large area cerebral infarction, encephalitis, epilepsy); cardiac QTc interval > 450ms;
  • Currently or have been diagnosed with other major diseases (such as coronary heart disease, pulmonary heart disease, etc.)
  • Those who are currently or have been diagnosed with other mental disorders other than major depressive disorder (except for anxiety disorder);
  • Patients who have a serious risk of suicide or who have had suicide attempts;
  • Those who are using or have been treated with escitalopram oxalate are not effective;
  • Those who are participating in or have participated in vagus nerve or transcranial electrical stimulation for less than 3 months;
  • MRI scan taboos and high-risk groups;
  • Pregnancy, breastfeeding or planning for pregnancy during the trial;
  • Refusal to sign informed consent.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

90 participants in 3 patient groups

drug treatment and active VNS
Experimental group
Description:
At the same time, actice VNS, escitalopram oxalate tablets were treated for 2 months.
Treatment:
Drug: drug treatment
Device: Transcutaneous electrical vagus nerve stimulation
drug treatment and sham VNS
Sham Comparator group
Description:
It received oxacillin oxalate tablets and sham VNS for 2 months.
Treatment:
Drug: drug treatment
Device: Sham vagus nerve stimulation
drug treatment
Other group
Description:
The dose of escitalopram oxalate tablets was maintained at 10-20mg/ day without VNS stimulation.
Treatment:
Drug: drug treatment

Trial contacts and locations

1

Loading...

Central trial contact

Yihuan Chen; Huaning Wang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems